| Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More | Frank Vinluan | 06/19/20 | National |
| In Microbiome Milestone, Finch Therapeutics C. diff Pill Bests Placebo | Sarah de Crescenzo | 06/19/20 | Boston |
| Engrail Therapeutics Launches With $32M to Develop New Neuro Drugs | Sarah de Crescenzo | 06/18/20 | San Diego |
| Orca Bio Surfaces With $192M and Recipes for “Custom” Cell Therapies | Frank Vinluan | 06/17/20 | San Francisco |
| Frazier Launches Lassen to Advance Antibodies Against Fibrosis, Cancer | Sarah de Crescenzo | 06/17/20 | San Diego |
| C4 Therapeutics Adds $170M to Test Protein Degraders in the Clinic | Sarah de Crescenzo | 06/16/20 | Boston |
| GSK Expands Synthetic Lethality Scope With $120M Ideaya Bio Alliance | Frank Vinluan | 06/16/20 | San Francisco |
| Akili Interactive’s Video Game for ADHD Gets the FDA All Clear | Frank Vinluan | 06/15/20 | Boston |
| FDA Reverses Authorization for Use of Antimalarials to Treat COVID-19 | Sarah de Crescenzo | 06/15/20 | National |
| GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track | Mandy Jackson | 06/12/20 | National |
| Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More | Sarah de Crescenzo | 06/12/20 | National |
| Novo Nordisk Strikes a $725M Deal for AstraZeneca Spinout Corvidia | Frank Vinluan | 06/11/20 | Boston |
| Moderna Finalizes Plan, Dose for Phase 3 Test of mRNA COVID Vaccine | Frank Vinluan | 06/11/20 | Boston |
| Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes | Frank Vinluan | 06/11/20 | Boston |
| Melinta Expands Antibiotics Lineup With $39M Tetraphase Acquisition | Frank Vinluan | 06/09/20 | New York |
| CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain” | Frank Vinluan | 06/09/20 | Boston |
| Sarepta Eyes Key Test for Gene Therapy in Rare Muscular Dystrophy | Sarah de Crescenzo | 06/08/20 | Boston |
| Akouos Aims for an IPO to Advance Hearing Loss Gene Therapy to Clinic | Frank Vinluan | 06/08/20 | Boston |
| Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More | Frank Vinluan | 06/05/20 | National |
| Atlas Venture Raises $400M Fund to Seed Another New Set of Biotechs | Sarah de Crescenzo | 06/05/20 | Boston |
| Cullinan Oncology Reels In $98M to Advance Cancer Drug Pipeline | Frank Vinluan | 06/04/20 | Boston |
| Accent, AstraZeneca Ink Cancer Drug Deal to Block RNA-Modifying Proteins | Sarah de Crescenzo | 06/04/20 | Boston |
| NodThera Adds $55M to Advance Drugs to Better Regulate Inflammation | Sarah de Crescenzo | 06/03/20 | Boston |
| Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact | Frank Vinluan | 06/01/20 | New York |
| Forma Therapeutics Eyes IPO to Advance Sickle Cell, Prostate Cancer Drugs | Sarah de Crescenzo | 05/29/20 | Boston |
| After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO | Frank Vinluan | 05/29/20 | Boston |
| Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More | Sarah de Crescenzo | 05/29/20 | National |
| New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech | Editors | 05/27/20 | Boston |
| COVID-19 Sparks New Opportunities for Digital Health Companies | Frank Vinluan | 05/26/20 | Boston |
| Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq | Frank Vinluan | 05/22/20 | National |
